Drug Profile


Alternative Names: AS-902330; FGF-18; rhFGF-18; Zfgf5

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZymoGenetics
  • Developer Merck Serono; Molecular Therapeutics; Nordic Bioscience; Pfizer
  • Class Fibroblast growth factors; Neuroprotectants
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis
  • Discontinued Cartilage disorders; Stroke

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 23 Jul 2015 Merck and Nordic Bioscience collaborate for the development of sprifermin
  • 10 Sep 2013 EMD Serono completes a phase II trial for Cartilage disorders (Cartilage injury of the knee; Adjunctive treatment) in Belgium (EudraCT2012-001431-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top